2,5-Dimethoxy-4-cyanoamphetamine
(Redirected from DOCN)
 | |
| Clinical data | |
|---|---|
| Other names | DOCN; 2,5-Dimethoxy-4-cyanoamphetamine; 4-Cyano-2,5-dimethoxyamphetamine |
| Drug class | Serotonergic agent; Serotonin 5-HT2 receptor modulator |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C12H16N2O2 |
| Molar mass | 220.272 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
2,5-Dimethoxy-4-cyanoamphetamine (DOCN) is a serotonergic drug of the phenethylamine, amphetamine, and DOx families.[1][2][3] It is a DOx derivative with a cyano group (–C≡N) at the 4 position of the molecule.[1][2][3]
Use and effects
[edit]The effects of DOCN in humans and whether it is a psychedelic are unknown.[1]
Interactions
[edit]Pharmacology
[edit]DON shows much lower affinities for the serotonin 5-HT2 receptors than other DOx drugs.[4][2][3] However, DOCN also showed by far the greatest degree of selectivity for the serotonin 5-HT2A receptor over the serotonin 5-HT2C receptor (22-fold) of any other assessed DOx drug.[5][6][2] Applying this strategy (i.e., cyano substitution) to the 25-NB series resulted in the discovery of 25CN-NBOH, one of the most selective serotonin 5-HT2A receptor agonists discovered to date.[5][7]
Chemistry
[edit]Analogues
[edit]Related drugs include DON, 2C-N, DOA, 2C-CN, 25CN-NBOH, and 25CN-NBOMe.[8][9][3][10]
History
[edit]DOCN was first described in the scientific literature by Richard Glennon and colleagues by 1989.[9][3]
Society and culture
[edit]Legal status
[edit]Canada
[edit]DOCN is a controlled substance in Canada under phenethylamine blanket-ban language.[11]
United States
[edit]DOCN is not a controlled substance in the United States as of 2011.[1]
See also
[edit]References
[edit]- 1 2 3 4 Shulgin A, Manning T, Daley PF (2011). "#55. DOCN". The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. Vol. 1. Berkeley, CA: Transform Press. pp. 105–106. ISBN 978-0-9630096-3-0. OCLC 709667010.
- 1 2 3 4 Nelson DL, Lucaites VL, Wainscott DB, Glennon RA (January 1999). "Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors". Naunyn-Schmiedeberg's Archives of Pharmacology. 359 (1): 1–6. doi:10.1007/pl00005315. PMID 9933142.
- 1 2 3 4 5 Seggel MR, Yousif MY, Lyon RA, Titeler M, Roth BL, Suba EA, et al. (March 1990). "A structure-affinity study of the binding of 4-substituted analogues of 1-(2,5-dimethoxyphenyl)-2-aminopropane at 5-HT2 serotonin receptors". Journal of Medicinal Chemistry. 33 (3): 1032–1036. doi:10.1021/jm00165a023. PMID 2308135.
- ↑ Trachsel D (2003). "Synthesis of Novel (Phenylalkyl)amines for the Investigation of Structure–Activity Relationships, Part 3: 4-Ethynyl-2,5-dimethoxyphenethylamine (=4-Ethynyl-2,5-dimethoxybenzeneethanamine; 2C-YN)". Helvetica Chimica Acta. 86 (8): 2754–2759. doi:10.1002/hlca.200390224. ISSN 0018-019X.
The Table summarizes some physicochemical data for the ethynyl group compared to other 4-substituents resulting in some of the most-potent 4-substituted 2,5-dimethoxy-α-methylbenzeneethanamines 2a ± d investigated in in vitro and in vivo studies [3j] [6] (compound 2d had considerably lower affinity at 5-HT2A2) sites [4 f] [6] but is used for structural comparison). [...] A Hansch analysis of a series of 4-substituted 2,5-dimethoxyamphetamines [6] gave a significant correlation between 5-HT2A affinity and the hydrophobicity of the 4- substituents. The measured 5-HT2A binding data for compound 2d bearing the 4-CN substituent showed an affinity of approximately two orders of magnitude lower than that of 2a,b [4f] [6]. For the binding affinity at the 5-HT2A receptor, the comparison of the physicochemical data for 4-substituents (Table) suggests that compound 1 should have substantially higher affinity than 4-cyano-2,5-dimethoxyamphetamine (2d; DOCN) or the α-demethyl congener thereof.
- 1 2 Halberstadt AL (2017). Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens. Current Topics in Behavioral Neurosciences. Vol. 32. pp. 283–311. doi:10.1007/7854_2016_64. ISBN 978-3-319-52442-9. PMID 28097528.
Similar to other classes of hallucinogens, NBOMes act as 5-HT2C receptor agonists and are relatively nonselective for 5-HT2A vs. 5-HT2C sites [39]. Given their high affinity and efficacy at 5-HT2A receptors, NBOMes have been developed as 5-HT2A agonist radioligands [50] and as PET tracers [51, 52]. Such work has also encouraged development of NBOMes exhibiting selectivity for 5-HT2A receptors compared with 5-HT2C sites. In contrast to other phenylisopropylamines, 2,5-dimethoxy4-cyanoamphetamine (DOCN, Fig. 6) exhibits moderate (22-fold) selectivity for human 5-HT2A (Ki = 45.7 nM) vs. 5-HT2C (Ki = 1,011 nM) sites labeled with [125I]DOI [46], indicating that 4-cyano substitution represents a potential strategy to augment 5-HT2A selectivity. Applying this strategy to the NBOMe class led to the discovery of N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenethylamine (25CN-NBOH), which is reportedly 100-fold selective for 5-HT2A receptors (Ki = 1.3 nM vs. [3H]ketanserin) compared with 5-HT2C receptors (Ki = 132 nM vs. [3H]mesulergine) [25]. However, according to a more recent investigation using the same antagonist radioligands, 25CN-NBOH is only 23-fold selective for 5-HT2A receptors (Ki = 2.2 nM) relative to 5-HT2C sites (Ki = 49.8 nM) [38]. Although the selectivity of 25CN-NBOH may be less than was initially believed, it still exhibits moderate 5-HT2A selectivity. [...] Fig. 6 Structures of the 4-cyano-substituted phenylalkylamines DOCN and 25CN-NBOH [...]
- ↑ Blaazer AR, Smid P, Kruse CG (September 2008). "Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors". ChemMedChem. 3 (9): 1299–1309. doi:10.1002/cmdc.200800133. PMID 18666267.
A near unity slope was found for 5-HT2A and 5-HT2C receptor affinity correlations, revealing a close correspondence. The only exception was the 4-cyano analogue 24 (DOCN), with a 22-fold higher affinity for 5-HT2A (Ki=45.7 nm) over 5-HT2C (Ki=1011 nm).[63]
- ↑ Poulie CB, Jensen AA, Halberstadt AL, Kristensen JL (December 2020). "DARK Classics in Chemical Neuroscience: NBOMes". ACS Chemical Neuroscience. 11 (23): 3860–3869. doi:10.1021/acschemneuro.9b00528. PMC 9191638. PMID 31657895.
- ↑ Coutts RT, Malicky JL (1 May 1973). "The Synthesis of Some Analogs of the Hallucinogen 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM)". Canadian Journal of Chemistry. 51 (9): 1402–1409. doi:10.1139/v73-210. ISSN 0008-4042.
- 1 2 Glennon RA, Seggel MR (14 November 1989). "Interaction of Phenylisopropylamines with Central 5-HT2 Receptors: Analysis by Quantitative Structure—Activity Relationships". Probing Bioactive Mechanisms. Vol. 413. Washington, DC: American Chemical Society. pp. 264–280. doi:10.1021/bk-1989-0413.ch018. ISBN 978-0-8412-1702-7.
- ↑ Jensen AA, Halberstadt AL, Märcher-Rørsted E, Odland AU, Chatha M, Speth N, et al. (July 2020). "The selective 5-HT2A receptor agonist 25CN-NBOH: Structure-activity relationship, in vivo pharmacology, and in vitro and ex vivo binding characteristics of [3H]25CN-NBOH". Biochemical Pharmacology. 177 113979. doi:10.1016/j.bcp.2020.113979. PMID 32298690.
- ↑ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.